Physician profile
John E Schulze
NPI 1770550378
$7,685.95
in general payments reported to CMS, 2019-2025
41 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $791 · 2021: $1,162 · 2022: $1,273 · 2023: $1,268 · 2024: $1,204 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,451 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,451.14 |
| Education | $129.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,048.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,032.69 | 2019-2025 | Mounjaro, Zepbound, Omvoh |
| Astrazeneca Pharmaceuticals Lp | $943.76 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $604.38 | 2021-2025 | Vraylar |
| Glaxosmithkline, LLC. | $456.61 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $353.92 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.14 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $340.96 | 2020-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $269.21 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.90 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $138.41 | 2019-2025 | Austedo Xr |
| Pfizer INC. | $130.05 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $119.04 | 2020 | |
| Paratek Pharmaceuticals, INC. | $118.99 | 2023-2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.20 | 2019-2025 | Jardiance, Tradjenta |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $108.40 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $108.31 | 2022 | |
| Astellas Pharma US INC | $99.69 | 2023-2024 | Veozah |
| Alexion Pharmaceuticals, INC. | $96.62 | 2019 | |
| Merck Sharp & Dohme LLC | $96.33 | 2019-2020 | |
| Amgen INC. | $88.56 | 2022-2025 | Otezla, Repatha, Repatha |
| Shire North American Group INC | $81.80 | 2019 | |
| Dexcom, INC. | $75.29 | 2021-2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $74.85 | 2023-2025 | Accrufer |
| Genentech, INC. | $72.89 | 2020 | |
| Phathom Pharmaceuticals, INC. | $68.56 | 2023-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $66.07 | 2020-2024 | Seglentis, Livalo, Zoryve |
| Novartis Pharmaceuticals Corporation | $65.99 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $65.34 | 2022 | |
| Abbott Laboratories | $51.83 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Alk-Abello, INC | $51.45 | 2024 | Odactra, Ragwitek, Grastek |
| Baxter Healthcare | $41.19 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Biohaven Pharmaceuticals, INC. | $35.63 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.19 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.84 | 2023 | Quviviq |
| Exact Sciences Corporation | $22.37 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $21.75 | 2021 | |
| Hologic Sales and Service, LLC | $16.92 | 2021 | |
| Nevro Corp. | $15.99 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.09 | 2023 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schulze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.